Poolbeg Pharma plc – Significant POLB 001 Patent Granted in United States
Immunomodulator II patent grant further strengthens robust intellectual property portfolio for partnering
1 May 2024 - Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that, further to its announcement on 20 March 2024, the Company has received the fully granted patent from the US Patent Office for its Immunomodulator II patent application.
